Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03661866 · ClinicalTrials.gov registry record
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
A clinical trial of Atopic Dermatitis and Psoriasis, sponsored by Target PharmaSolutions.
- Active
- Registry status
- 15,000
- Enrollment target
- 20
- Study locations
NCT03661866: Active study of Atopic Dermatitis and Psoriasis, sponsored by Target PharmaSolutions.
NCT03661866 is a study of Atopic Dermatitis and Psoriasis that is active but no longer recruiting, run by Target PharmaSolutions. The registered enrollment target is 15,000 participants, above the 509-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (2847% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03661866, a study of Atopic Dermatitis and Psoriasis, is active but no longer recruiting, sponsored by Target PharmaSolutions.
- ACTIVE NOT RECRUITING
- Registry status
- 15,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Primary Outcome
Enable characterization of IMISC disease activity and comorbid medical conditions over time.
Conditions Studied
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Center for Dermatology Cosmetic and Laser Surgery - Fremont
- University of California - Irvine
- University of California - San Diego/Rady Children's Hospital - San Diego
Arkansas
- Johnson Dermatology - Fort Smith
- University of Arkansas for Medical Sciences - Little Rock
- Arkansas Dermatology - Little Rock
Florida
- Feinstein Dermatology and Cosmetic Surgery - Hollywood
- Academic Alliance in Dermatology - Tampa
- Integrated Dermatology of West Palm Beach - West Palm Beach
Massachusetts
- Integrated Dermatology of Massachusetts - Quincy
- University of Massachusetts Medical School - Worcester
Arizona
- Clear Dermatology & Aesthetics Center/Investigative MD - Scottsdale
District of Columbia
- George Washington University - Washington D.C.
Illinois
- Lurie Children's Hospital/Northwestern University - Chicago
Indiana
- Dawes Fretzin Dermatology/ Dawes Fretzin Clinical Research Group - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,000 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2050-12 |
What the registry record for NCT03661866 still lists
NCT03661866 is an observational study that tracks outcomes without assigning an intervention. Its 15,000 participants enrollment target places it among the larger protocols in the corpus, above the 509-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (2847% higher).
The record links to 6 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.
NCT03661866 names 20 study sites across 12 states, led by California, Arkansas, Florida.
Frequently Asked Questions
What is clinical trial NCT03661866 about?
NCT03661866 is a clinical study titled "A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC". TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and com...
What is the current status of trial NCT03661866?
This trial is currently active not recruiting. The enrollment target is 15,000 participants. The study started on 2018-12-21. Estimated completion is 2050-12.
What conditions does trial NCT03661866 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Alopecia Areata, Chronic Spontaneous Urticaria.
Who is sponsoring clinical trial NCT03661866?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03661866 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03661866's enrollment target sits among peer trials
15,000 2nd of 150 the highest of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
- NCT02253251 · 15,000 participants
Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI